Relief therapeutics « Terug naar discussie overzicht

quote:

DeZwarteRidder schreef op 29 augustus 2020 09:49:

[...]
Exercise of a call option in which the reporting party had the obligation to sell 66 666 667 shares at a unit price of CHF 0.01 on demand of the other party, the main shareholder of Relief.

quote:

MisterBlues schreef op 29 augustus 2020 10:19:

Wat denken jullie hiervan?

The lack of a selloff at the end of the trading day today tells me the swing traders/profit takers have pretty much been cleaned out of the stock. The dips although not fun to watch I think have done a good job of cleaning them out. We are increasingly trading range bound as well which means I think everyone is just in a "wait and see" mode at this point. We may trend up and have occasional bursts as people get FOMO when the price moves, but I think we will trend upward until the FDA approval comes up. I honestly don't see us moving over $1.00, probably moving up to max $0.80 level until FDA news hits. But obviously ... an FDA approval sets this thing off to the races ($5-$10B market cap probably near instantly on the news imho). And I think that Javitt and crew have the big pharma partnership PR already typed up and ready to go the instant FDA approval hits so I do think our "little drug" will instantly be on the front page news all over the country and world nearly overnight. The news will be that there is a new drug for Covid and Merck (etc.) is mfg and distributing under an exclusive deal with (until then unknown) NeuroRx and Relief Therapeutics. And as mentioned before obviously other than being a really big deal the partnership with big pharma will give RLF-100 instant credibility and instant notoriety. Javitt and crew know exactly what they are doing in terms of "the biggest bang for the buck".

quote:

Beso schreef op 29 augustus 2020 11:29:

[...]
De nagel op de kop denk ik. In vorige berichten werd geschreven dat Relief zich bij manier van spreken de kaas van tussen de boterham liet nemen. Integendeel, die weten goed wat voor unieke kans die hebben en dat ze grote bedrijven nodig hebben om zich waar te maken maar zullen hun vel niet goedkoop verkopen. Wat de koersevolutie deze week betreft heeft die goed stand gehouden en dat in een vaak rood getint algemeen beursklimaat. Kan me goed voor stellen dat de meesten die er nu in zitten er in blijven tot nieuws komt van FDA. Hopelijk verdere genezing brandweerman, ook uiteraard vooreerst voor de man in kwestie zelf, die RLF zal kunnen helpen alvast richting 0,8 te gaan alvorens FDA uitspraak..

quote:

MisterBlues schreef op 29 augustus 2020 10:19:

Wat denken jullie hiervan?

The lack of a selloff at the end of the trading day today tells me the swing traders/profit takers have pretty much been cleaned out of the stock. The dips although not fun to watch I think have done a good job of cleaning them out. We are increasingly trading range bound as well which means I think everyone is just in a "wait and see" mode at this point. We may trend up and have occasional bursts as people get FOMO when the price moves, but I think we will trend upward until the FDA approval comes up. I honestly don't see us moving over $1.00, probably moving up to max $0.80 level until FDA news hits. But obviously ... an FDA approval sets this thing off to the races ($5-$10B market cap probably near instantly on the news imho). And I think that Javitt and crew have the big pharma partnership PR already typed up and ready to go the instant FDA approval hits so I do think our "little drug" will instantly be on the front page news all over the country and world nearly overnight. The news will be that there is a new drug for Covid and Merck (etc.) is mfg and distributing under an exclusive deal with (until then unknown) NeuroRx and Relief Therapeutics. And as mentioned before obviously other than being a really big deal the partnership with big pharma will give RLF-100 instant credibility and instant notoriety. Javitt and crew know exactly what they are doing in terms of "the biggest bang for the buck".

quote:

DeZwarteRidder schreef op 29 augustus 2020 11:42:

[...]
Relief moet alles uitbesteden, dus er blijft verdraaid weinig winst over (if any).

quote:

DeZwarteRidder schreef op 29 augustus 2020 12:02:

GEM gaat dus 66 miljoen aandelen dumpen.

quote:

DeZwarteRidder schreef op 29 augustus 2020 12:02:

GEM gaat dus 66 miljoen aandelen dumpen.

quote:

MisterBlues schreef op 29 augustus 2020 10:19:

Wat denken jullie hiervan?

The lack of a selloff at the end of the trading day today tells me the swing traders/profit takers have pretty much been cleaned out of the stock. The dips although not fun to watch I think have done a good job of cleaning them out. We are increasingly trading range bound as well which means I think everyone is just in a "wait and see" mode at this point. We may trend up and have occasional bursts as people get FOMO when the price moves, but I think we will trend upward until the FDA approval comes up. I honestly don't see us moving over $1.00, probably moving up to max $0.80 level until FDA news hits. But obviously ... an FDA approval sets this thing off to the races ($5-$10B market cap probably near instantly on the news imho). And I think that Javitt and crew have the big pharma partnership PR already typed up and ready to go the instant FDA approval hits so I do think our "little drug" will instantly be on the front page news all over the country and world nearly overnight. The news will be that there is a new drug for Covid and Merck (etc.) is mfg and distributing under an exclusive deal with (until then unknown) NeuroRx and Relief Therapeutics. And as mentioned before obviously other than being a really big deal the partnership with big pharma will give RLF-100 instant credibility and instant notoriety. Javitt and crew know exactly what they are doing in terms of "the biggest bang for the buck".

quote:

DeZwarteRidder schreef op 29 augustus 2020 11:42:

[...]
Relief moet alles uitbesteden, dus er blijft verdraaid weinig winst over (if any).

quote:

Mozes kriebel schreef op 29 augustus 2020 12:15:

[...]
Beste ridder volgens mij weet je donders goed dat dit gewoon een afgesproken deal is die in voorjaar al gesloten is. Deze aandelen zijn niet op de markt gekomen is ter financiering van de onderzoeken. Rlf heeft daarvoor afspraken met GEM gemaakt. Onderzoek start komende week dus logisch dat ze dit nu doen. Ze mogen dit jaar nog een kleine hoeveelheid (geloof 12 miljoen) bij GEM uitzetten ter financiering van de onderzoeken. Niets aan de hand. Op cash is hierover in voorjaar al lange discussie gevoerd. Wordt pas probleem als GEM besluit de aandelen echt te verkopen. Daar is geen sprake nu van.

quote:

DeZwarteRidder schreef op 29 augustus 2020 12:50:

[...]
Wat een geklets: deze deal heeft niks te maken met het onderzoek.

Dezer deal gaat geheel buiten Relief om en levert geen geld op voor Relief, daarentegen is het wel zeker dat GEM deze aandelen gaat dumpen want anders hadden ze deze calloptie niet uitgeoefend.

quote:

Mozes kriebel schreef op 29 augustus 2020 12:33:

googlenextnews.com/new-drug-aviptadil...

quote:

Kleintje66 schreef op 29 augustus 2020 12:52:

[...]
Het was juist onderdeel van het leveren van cash aan Relief.

quote:

Mozes kriebel schreef op 29 augustus 2020 12:33:

googlenextnews.com/new-drug-aviptadil...

quote:

DeZwarteRidder schreef op 29 augustus 2020 14:14:

[...]
Grapjas: het heeft een poep en een scheet opgeleverd en die medewerker van Relief zit te balen als een stekker omdat hij ca 35 miljoen is misgelopen.

quote:

DeZwarteRidder schreef op 29 augustus 2020 14:15:

[...]
Oud nieuws in een Indiase krant.